Citation Impact
Citing Papers
Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study
2010 Standout
Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells
2013 StandoutScience
A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF Inhibition
2013
Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials
2015
A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma
2012
Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non–Small Cell Lung Cancer
2013
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
2011 Standout
High burden and pervasive positive selection of somatic mutations in normal human skin
2015 StandoutScience
Final Version of 2009 AJCC Melanoma Staging and Classification
2009 Standout
TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF- Mutant Melanoma
2013
Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment
2018 StandoutNobel
Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
2010 Standout
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Meta-regression models to address heterogeneity and inconsistency in network meta-analysis of survival outcomes
2012
Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors
2016
Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis
2015
Chest electrical impedance tomography examination, data analysis, terminology, clinical use and recommendations: consensus statement of the TRanslational EIT developmeNt stuDy group
2016 Standout
Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review
2017
Trametinib (GSK1120212) in the treatment of melanoma
2013
MEK1/2 inhibitors in the treatment of gynecologic malignancies
2014
Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
2014 Standout
New drugs in melanoma: It’s a whole new world
2011
Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials
2003
Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
2010 StandoutNobel
Oncology Meets Immunology: The Cancer-Immunity Cycle
2013 Standout
MEK in cancer and cancer therapy
2013
A view on drug resistance in cancer
2019 StandoutNature
Prognostic Factors That Determine the Long-Term Survival of Patients with Unresectable Metastatic Melanoma
2008
Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study
2014
Tumor adaptation and resistance to RAF inhibitors
2013
Transient MEK inhibitor-associated retinopathy in metastatic melanoma
2014
Current and future adjuvant immunotherapies for melanoma: Blockade of cytotoxic T-lymphocyte antigen-4 as a novel approach
2010
The biology and management of non-small cell lung cancer
2018 StandoutNature
Lessons from the Cancer Genome
2013
Inhibition of both BRAF and MEK in BRAFV600E mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties
2013
Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?
2013
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
2014 StandoutNature
AI in health and medicine
2022 Standout
The mini-driver model of polygenic cancer evolution
2015 StandoutNobel
A melanocyte lineage program confers resistance to MAP kinase pathway inhibition
2013 Nature
The Cancer Genome Atlas Pan-Cancer analysis project
2013 Standout
Merkel cell carcinoma
2017
Super-Enhancers in the Control of Cell Identity and Disease
2013 Standout
The yeast chromatin remodeler Rsc1-RSC complex is required for transcriptional activation of autophagy-related genes and inhibition of the TORC1 pathway in response to nitrogen starvation
2015 StandoutNobel
Pancreatic Adenocarcinoma
2014 Standout
Cellular senescence in ageing: from mechanisms to therapeutic opportunities
2020 Standout
Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
2016 Standout
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Multimodal biomedical AI
2022 Standout
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Brain metastases: current management and new developments
2008
BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease
2014
Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
2013
Liquid biopsies come of age: towards implementation of circulating tumour DNA
2017 Standout
Advances in systemic treatment of melanoma
2010
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
2021 StandoutNobel
Emerging Biological Principles of Metastasis
2017 Standout
Emerging Role of mTOR in the Response to Cancer Therapeutics
2016
Case 21-2013
2013
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
EMT: 2016
2016 Standout
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types
2013
The Emerging Hallmarks of Cancer Metabolism
2016 Standout
Cancer immunotherapy comes of age
2011 StandoutNature
Management of Metastatic Melanoma 2005
2006
The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: The Bristol-Myers Squibb experience
2014
PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis
2016
Prognostic Impact of Autophagy Biomarkers for Cutaneous Melanoma
2016
Prospects for MEK inhibitors for treating cancer
2014
Harnessing multimodal data integration to advance precision oncology
2021
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
2010 Standout
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial
2012
Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?
2004
The PI3K Pathway in Human Disease
2017 Standout
Discovery and saturation analysis of cancer genes across 21 tumour types
2014 StandoutNature
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
2012
Microenvironmental regulation of tumor progression and metastasis
2013 Standout
MEK Inhibition in the Treatment of Advanced Melanoma
2013
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Recent advances in the prevention and treatment of skin cancer using photodynamic therapy
2010
Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer
2004
Copper is required for oncogenic BRAF signalling and tumorigenesis
2014 Nature
Combining Targeted Therapy With Immunotherapy in BRAF-Mutant Melanoma: Promise and Challenges
2014
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
2015 Standout
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
2013 StandoutNobel
Assessment of Accuracy of an Artificial Intelligence Algorithm to Detect Melanoma in Images of Skin Lesions
2019
Lipid Nanoparticles Delivering Constitutively Active STING mRNA to Stimulate Antitumor Immunity
2022 StandoutNobel
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
2018 Standout
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer
2015
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
2015 Standout
Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanoma
2017
Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group
2006
Copper induces cell death by targeting lipoylated TCA cycle proteins
2022 StandoutScience
Phase II, Randomized, Controlled, Double-Blinded Trial of Weekly Elesclomol Plus Paclitaxel Versus Paclitaxel Alone for Stage IV Metastatic Melanoma
2009
Diagnosis and Treatment of mela-noma Brain Metastasis: A Literature Review
2009
Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma
2009
Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma
2009
Emerging Targets in Photopharmacology
2016 StandoutNobel
Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma
2017
Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects
2011
Combining Immune Checkpoint Inhibitors and Kinase-Inhibiting Supramolecular Therapeutics for Enhanced Anticancer Efficacy
2016
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
Immune Checkpoint Blockade in Cancer Therapy
2015 Standout
Works of Peter Mohr being referenced
Dacarbazine and interferon α with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)
2001
Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma
2015
Effective photodynamic therapy of actinic keratoses on the head and face with a novel, self‐adhesive 5‐aminolaevulinic acid patch
2008
Biomarkers in melanoma
2009
A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma
2003
Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III Study
2004
Electrical impedance spectroscopy as a potential adjunct diagnostic tool for cutaneous melanoma
2013
Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (pembro; MK-3475) versus chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) advanced melanoma (MEL).
2015
Intermittent high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: Final analysis of a randomized phase III DeCOG-trial (NCT00226408).
2012
Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer.
1999
Health Initiatives for the Prevention of Skin Cancer
2014
Prospective Randomized Multicenter Adjuvant Dermatologic Cooperative Oncology Group Trial of Low-Dose Interferon Alfa-2b With or Without a Modified High-Dose Interferon Alfa-2b Induction Phase in Patients With Lymph Node–Negative Melanoma
2009
Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe
2017
Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
2012
Open-label, multicenter, single-arm phase II study (DeCOG-Trial) to further evaluate the efficacy and safety of ipilimumab in patients with cutaneous melanoma and rare subgroups.
2014